Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1232826.RAnP_g99rIxc1vFOYDrP1jMVU5EZuOGN4HHdlBmkJ6E90130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1232826.RAnP_g99rIxc1vFOYDrP1jMVU5EZuOGN4HHdlBmkJ6E90130_assertion type Assertion NP1232826.RAnP_g99rIxc1vFOYDrP1jMVU5EZuOGN4HHdlBmkJ6E90130_head.
- NP1232826.RAnP_g99rIxc1vFOYDrP1jMVU5EZuOGN4HHdlBmkJ6E90130_assertion description "[Beyond development, we can look into the effectiveness of already approved targeted therapies (eg, anti-BRAF(V600E) selective inhibitors, tyrosine kinase inhibitors, histone deacetylase inhibitors, inhibitors of DNA methylation, etc) to potentially test in ATC after learning the molecular mechanisms that aid in tumor progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1232826.RAnP_g99rIxc1vFOYDrP1jMVU5EZuOGN4HHdlBmkJ6E90130_provenance.
- NP1232826.RAnP_g99rIxc1vFOYDrP1jMVU5EZuOGN4HHdlBmkJ6E90130_assertion evidence source_evidence_literature NP1232826.RAnP_g99rIxc1vFOYDrP1jMVU5EZuOGN4HHdlBmkJ6E90130_provenance.
- NP1232826.RAnP_g99rIxc1vFOYDrP1jMVU5EZuOGN4HHdlBmkJ6E90130_assertion SIO_000772 25347569 NP1232826.RAnP_g99rIxc1vFOYDrP1jMVU5EZuOGN4HHdlBmkJ6E90130_provenance.
- NP1232826.RAnP_g99rIxc1vFOYDrP1jMVU5EZuOGN4HHdlBmkJ6E90130_assertion wasDerivedFrom befree-2016 NP1232826.RAnP_g99rIxc1vFOYDrP1jMVU5EZuOGN4HHdlBmkJ6E90130_provenance.
- NP1232826.RAnP_g99rIxc1vFOYDrP1jMVU5EZuOGN4HHdlBmkJ6E90130_assertion wasGeneratedBy ECO_0000203 NP1232826.RAnP_g99rIxc1vFOYDrP1jMVU5EZuOGN4HHdlBmkJ6E90130_provenance.